此次FDA授予突破性疗法认定主要是基于TROPION-Lung05临床2期试验数据,并加上TROPION-Lung01临床3期试验的支持性数据。今年美国临床肿瘤学会(ASCO)年会中所公布的TROPION-Lung05试验的部分结果显示,18名具有目 ...
At the 2024 annual meeting of the American Society of Hematology (ASH), held on 7 December in San Diego, California, ...
Data from Eli Lilly and AstraZeneca could help doctors decide treatment order in chronic lymphocytic leukemia. Elsewhere, ...
Trying to break from the decade-old practice of using BTK inhibitors indefinitely to treat blood cancer, AstraZeneca has ...
AstraZeneca is getting ready to step on the gas in the world of bispecific T cell engagers. The company presented some of its ...
The U.S. Food and Drug Administration has approved AstraZeneca blockbuster drug Imfinzi to treat some adults with ...
AstraZeneca has picked off another label expansion for its cancer blockbuster Imfinzi (durvalumab) as the FDA has ...
AstraZeneca AZN and its Japanese partner Daiichi Sankyo announced that the FDA has granted a Breakthrough Therapy designation ...
AstraZeneca and Daiichi Sankyo have shared the data they believe can secure approval for datopotamab deruxtecan (Dato-DXd) at ...
The FDA has approved the drug durvalumab for adults with limited-stage small-cell lung cancer (LS-SCLC) whose disease hasn’t gotten worse after getting platinum-based chemo and radiation at the same ...
AstraZeneca's Imfinzi (durvalumab) has been approved in the US for the treatment of adult patients with limited-stage small ...